Apixaban Dose in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention

Figures

• 

  Figure 1. Apixaban Dose-Reduction Group and Outcomes Event rates of major/CRNM bleeding, death or rehospitalization, and death or ischemic events. CRNM = clinically relevant nonmajor.

• 

  Figure 2. Randomized Treatment and Clinical Outcomes According to Apixaban Dose Association between randomized treatment (apixaban vs VKA) and clinical outcomes by standard or reduced dose status (appropriately and inappropriately reduced). ISTH = International Society on Thrombosis and Haemostasis; VKA = vitamin K antagonist; other abbreviation as in Figure 1.

• 

  Central Illustration. Major and Clinically Relevant Nonmajor Bleeding, Death and Ischemic Events According to Apixaban Dose Received in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention AUGUSTUS trial sample and association between randomized treatment (apixaban vs VKA) and clinical outcomes by standard or reduced dose status (appropriately and inappropriately reduced). ACS = acute coronary syndrome; AF = atrial fibrillation; PCI = percutaneous coronary intervention; other abbreviations as in Figures 1 and 2.